文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

替奈普酶0.40 mg/kg与0.25 mg/kg对大血管闭塞性卒中血管内取栓前再灌注的影响:EXTEND-IA TNK Part 2随机临床试验

Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该随机临床试验在澳大利亚27家医院和新西兰1家医院纳入300例大血管闭塞性缺血性卒中患者,比较替奈普酶0.40 mg/kg与0.25 mg/kg在血管内取栓前对再灌注的影响。主要结局显示两组再灌注率均为19.3%,无显著差异;功能结局、死亡和症状性颅内出血亦无显著差异。

要点

  • 0.40 mg/kg与0.25 mg/kg替奈普酶取栓前再灌注率均为19.3%,无显著差异。
  • 功能结局、全因死亡和症状性颅内出血在两组间无显著差异。
  • 在大血管闭塞性卒中拟行取栓患者中,0.40 mg/kg未显示优于0.25 mg/kg。

核心结论

  • 在大血管闭塞性缺血性卒中患者中,替奈普酶0.40 mg/kg与0.25 mg/kg相比未显著改善血管内取栓前脑再灌注。
  • 研究结果提示,对于计划行血管内取栓的大血管闭塞性卒中患者,0.40 mg/kg剂量并不优于0.25 mg/kg剂量。

研究设计与样本

  • 随机临床试验,在澳大利亚27家医院和新西兰1家医院进行,采用开放标签治疗和盲法评估影像学及临床结局。
  • 纳入标准为症状发作4.5小时内因颅内颈内动脉、基底动脉或大脑中动脉闭塞导致的缺血性卒中,符合标准静脉溶栓条件。
  • 干预为开放标签替奈普酶0.40 mg/kg(最大40 mg,n=150)或0.25 mg/kg(最大25 mg,n=150),在血管内取栓前团注。

主要发现

  • 6个次要结局中,4个功能结局在两组间均无显著差异。
  • 全因死亡:0.40 mg/kg组26例(17%) vs 0.25 mg/kg组22例(15%),未校正风险差2.7%(95%CI -5.6%至11.0%)。
  • 症状性颅内出血:0.40 mg/kg组7例(4.7%) vs 0.25 mg/kg组2例(1.3%),未校正风险差3.3%(95%CI -0.5%至7.2%)。

临床怎么用

  • 对于计划行血管内取栓的大血管闭塞性缺血性卒中患者,选择替奈普酶0.25 mg/kg剂量即可,0.40 mg/kg未显示额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular thrombectomy for ischemic stroke compared with alteplase. OBJECTIVE: To determine whether 0.40 mg/kg of tenecteplase safely improves reperfusion before endovascular thrombectomy vs 0.25 mg/kg of tenecteplase in patients with large vessel occlusion ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial at 27 hospitals in Australia and 1 in New Zealand using open-label treatment and blinded assessment of radiological and clinical outcomes. Patients were enrolled from December 2017 to July 2019 with follow-up until October 2019. Adult patients (N = 300) with ischemic stroke due to occlusion of the intracranial internal carotid, \basilar, or middle cerebral artery were included less than 4.5 hours after symptom onset using standard intravenous thrombolysis eligibility criteria. INTERVENTIONS: Open-label tenecteplase at 0.40 mg/kg (maximum, 40 mg; n = 150) or 0.25 mg/kg (maximum, 25 mg; n = 150) given as a bolus before endovascular thrombectomy. MAIN OUTCOMES AND MEASURES: The primary outcome was reperfusion of greater than 50% of the involved ischemic territory prior to thrombectomy, assessed by consensus of 2 blinded neuroradiologists. Prespecified secondary outcomes were level of disability at day 90 (modified Rankin Scale [mRS] score; range, 0-6); mRS score of 0 to 1 (freedom from disability) or no change from baseline at 90 days; mRS score of 0 to 2 (functional independence) or no change from baseline at 90 days; substantial neurological improvement at 3 days; symptomatic intracranial hemorrhage within 36 hours; and all-cause death. RESULTS: All 300 patients who were randomized (mean age, 72.7 years; 141 [47%] women) completed the trial. The number of participants with greater than 50% reperfusion of the previously occluded vascular territory was 29 of 150 (19.3%) in the 0.40 mg/kg group vs 29 of 150 (19.3%) in the 0.25 mg/kg group (unadjusted risk difference, 0.0% [95% CI, -8.9% to -8.9%]; adjusted risk ratio, 1.03 [95% CI, 0.66-1.61]; P = .89). Among the 6 secondary outcomes, there were no significant differences in any of the 4 functional outcomes between the 0.40 mg/kg and 0.25 mg/kg groups nor in all-cause deaths (26 [17%] vs 22 [15%]; unadjusted risk difference, 2.7% [95% CI, -5.6% to 11.0%]) or symptomatic intracranial hemorrhage (7 [4.7%] vs 2 [1.3%]; unadjusted risk difference, 3.3% [95% CI, -0.5% to 7.2%]). CONCLUSIONS AND RELEVANCE: Among patients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not significantly improve cerebral reperfusion prior to endovascular thrombectomy. The findings suggest that the 0.40-mg/kg dose of tenecteplase does not confer an advantage over the 0.25-mg/kg dose in patients with large vessel occlusion ischemic stroke in whom endovascular thrombectomy is planned. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03340493.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. JAMA. 2020. PMID: 32078683. doi:10.1001/jama.2020.1511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。